Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan + bevacizumab for brain metastases from non-small cell lung cancer
NL-OMON58778Phase 2Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan and bevacizumab in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Maastricht University Medical Center+. Primary endpoint: Brain metastasis objective response rate. Started Jul 2025; status: recruiting.
02
Drugs
sacituzumab govitecanbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NL-OMON58778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58778.